Geneva, November 1st, 2021 –In the week ahead, IGBA will renew its commitment to the collaborative effort to establish worldwide biosimilar policies that deliver better health outcomes and biologics access equity for more patients. The second Global Biosimilars Week will run from 1st to 5th November 2021 on social media, supported by a dedicated website globalbiosimilarsweek.org.
07 October, Athens, Greece. Health systems have been severely jolted by COVID-19, causing widespread disruption to the provision of health care worldwide. As countries shift to investment in healthcare system recovery and ongoing management of COVID-19, off-patent medicines will be critical to their success.
- Annual Conference Opening Remarks Suzette Kox (October 2021)
- Global regulators and coalition of pharma and vaccine manufacturing associations come together to discuss COVID-19 pandemic response (July 2021)
- IGBA Launches a Whitepaper: a Vision for the Global Generic and Biosimilar Medicines Industry (July 2021)
- IGBA Applauds UK MHRA Biosimilar Guidance Revision: Science-driven Evolution for Sustainable Access to Biologics (May 2021)